Experimental CAR T-Cell therapy takes on tough lupus cases
NCT ID NCT06984341
First seen Nov 01, 2025 · Last updated May 30, 2026 · Updated 33 times
Summary
This early-stage study tests an experimental treatment called P-CD19CD20-ALLO1 in 162 adults with severe lupus that hasn't improved with standard therapies. The treatment uses specially engineered immune cells to target and potentially reset the immune system. The main goals are to check safety and see if it can reduce disease activity, possibly allowing patients to stop other medications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham: The Kirklin Clinic
Birmingham, Alabama, 35233, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.